Recent Advances in Gut Microbiota Mediated Therapeutic Targets in Inflammatory Bowel Diseases: Emerging Modalities for Future Pharmacological Implications

Shamoon M1, Martin NM2, L O'Brien C3. Pharmacol Res. 2019 Aug 7:104344. doi: 10.1016/j.phrs.2019.104344. [Epub ahead of print]


Author information

Biology Section, Shandong Normal University Affiliated Senior School, Jinan 250001, PR China.

Medical School, The Australian National University, Canberra ACT 2600, Australia.

Medical School, The Australian National University, Canberra ACT 2600, Australia; IBD Research Group, Canberra Hospital, Canberra, Australia. Electronic address: claire.obrien@anu.edu.au.


The inflammatory bowel diseases (IBDs) are chronic inflammatory conditions, which are increasing in prevalence worldwide. The IBDs are thought to result from an aberrant immune response to gut microbes in genetically susceptible individuals. Dysbiosis of the gut microbiome, both functional and compositional, promotes patient susceptibility to colonization by pathobionts. Manipulating gut microbial communities and gut microbiota-immune system interactions to restore gut homeostasis or reduce inflammation are appealing therapeutic models. We discuss the therapeutic potential of precision microbiota editing, natural and engineered probiotics, the use of gut microbiota-derived metabolites in colitogenic phenotypes, and intestinal stem cells, in maintaining gut microbiota balance, restoring the mucosal barrier, and having positive immunomodulatory effects in experimental IBD. This review highlights that we are only just beginning to understand the complexity of the microbiota and how it can be manipulated for health benefits, including treatment and prevention of the clinical IBDs in future.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.